1stOncology™: Cancer Intelligence Service – Page 11672 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Sorrento Receives FDA IND Clearance to Initiate a Phase I Clinical Trial of its CD38 Antibody-Drug Conjugate (ADC) STI-6129 for Patients with Amyloidosis

On May 26, 2020 Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") reported it has received clearance from the U.S. Food and Drug Administration (FDA) for its investigational new drug (IND) application for STI-6129, a CD38-targeting antibody drug conjugate (ADC) (Press release, Sorrento Therapeutics, MAY 26, 2020, View Source [SID1234558450]). STI-6129 utilizes several technology platforms that are under development by Sorrento Therapeutics, including a CD38 specific antibody identified from its fully human G-MAB antibody library, its proprietary drug payload Duostatin 5 and its site-specific C-LOCK conjugation technology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

"That the FDA cleared our STI-6129 IND application to proceed to human trials is another important milestone for Sorrento," stated Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics. "Together with our CD38 CAR-T program, this has the potential to provide additional therapeutic options for patients in need. We are looking forward to further evaluating the safety and efficacy of STI-6129 in clinical trials."

Sorrento intends to initiate a phase I multicenter, open-label, dose-escalation clinical trial in patients with advanced relapsed and/or refractory systemic amyloid light chain (AL) amyloidosis with a primary objective to identify a phase 2 dose for STI-6129 based on its safety, preliminary efficacy and pharmacokinetic profile.

"This is Sorrento’s first ADC utilizing our site-specific C-LOCK conjugation technology that is advancing into clinical evaluation," said Dr. Hui Li, head of Sorrento’s ADC business unit, Levena Biopharma. "STI-6129 demonstrated an improved therapeutic index in animal models, as compared to traditional non-selective conjugates, and we look forward to potentially expanding its utilization into additional ADC programs."

Ribon Therapeutics to Present at the Jefferies Virtual Healthcare Conference

On May 26, 2020 Ribon Therapeutics, a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways, reported that Victoria Richon, Chief Executive Officer, will provide a corporate overview and an update on the company’s lead clinical program, PARP7 inhibitor RBN-2397, at the Jefferies 2020 Virtual Healthcare Conference (Press release, Ribon Therapeutics, MAY 26, 2020, View Source [SID1234558448]).

Jefferies Virtual Healthcare Conference – June 2-4, 2020
Corporate Presentation
Presenter: Victoria Richon, PhD – President and CEO
Date: June 2, 2020
Time: 3:00 p.m. EDT

HOOKIPA Pharma to Present at Jefferies Virtual Healthcare Conference

On May 26, 2020 HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, reported that HOOKIPA’s management team will participate and present at Jefferies Virtual Healthcare Conference, taking place June 2 – 4, 2020 (Press release, Hookipa Pharma, MAY 26, 2020, View Source [SID1234558447]).

Presentation: Wednesday, June 3, 2020 at 8:30 a.m. ET
The live audio webcast of the presentation held at Jefferies Virtual Healthcare Conference will be available within the Investors & Media section of HOOKIPA’s website at View Source An archived replay will be accessible for 30 days following the event.

Sierra Oncology Appoints Dr. Stephen Dilly as President and Chief Executive Officer

On May 26, 2020 Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, reported the appointment of Dr. Stephen Dilly as President and Chief Executive Officer, effective June 1, 2020 (Press release, Sierra Oncology, MAY 26, 2020, View Source [SID1234558446]). In addition, Dr. Dilly and Mr. Craig Collard have been appointed to the company’s Board of Directors.

"We are delighted to welcome Dr. Dilly to Sierra and look forward to his leadership as we continue to advance momelotinib and start to prepare for its potential commercialization. Stephen is a proven industry veteran with a track record of success, well-suited to shepherd the company through this evolution. We also welcome Craig Collard, who adds further commercial experience to our Board at this critical stage," said Mr. Robert Pelzer, Chairman of Sierra Oncology. "On behalf of the Board of Directors, I would like to sincerely thank Dr. Nick Glover for his commitment and dedication to Sierra and for guiding the renewed development of momelotinib to this late stage."

"I am excited to lead Sierra, which has already clearly defined the regulatory path for momelotinib, launched the MOMENTUM Phase 3 trial, and positioned this unique asset as a differentiated treatment that may address unmet needs in myelofibrosis, representing a substantial market opportunity," said Dr. Dilly. "I look forward to working with the Sierra team and Board of Directors to drive this promising investigational therapy forward through its anticipated final phase of clinical development and begin the company’s transition into a commercially focused entity."

Dr. Stephen Dilly brings three decades of executive management experience in the biopharmaceutical industry. Most recently, Dr. Dilly served as CEO and Board Member of Aimmune Therapeutics. Dr. Dilly has served in executive roles at Genentech, Chiron and SmithKline Beecham and has been associated with the development and launch of several marketed drugs. Dr. Dilly also currently serves on the Board of Directors of one public biotechnology company and several private companies. He holds an M.B.B.S. from the University of London and a Ph.D. in Cardiac Physiology from University of London.

Mr. Craig Collard is currently the CEO of Veloxis Pharmaceutics, Inc., a transplant focused pharmaceutical company, now a subsidiary of Asahi Kasei after its acquisition of Veloxis for $1.3 billion in 2020. Prior to this, he served as the CEO and Chairman of Cornerstone Therapeutics, Inc., a pharmaceutical company he founded in 2004, until February 2014 when the company was purchased by Chiesi Pharmaceuticals, Inc. Before founding Cornerstone, Mr. Collard served as President and CEO of Carolina Pharmaceuticals, Inc., a pharmaceutical company he founded in May 2003. From 1998 to 2003, Mr. Collard served in various commercial roles at Verum Pharmaceuticals, Inc., and DJ Pharma, Inc. Mr. Collard is a member of the Board of Directors of Veloxis, Opiant Pharmaceutics, Inc. and TerrAscend Corporation. Mr. Collard holds a B.S. in Engineering from the Southern College of Technology (now Southern Polytechnic State University) in Marietta, Georgia.

Sesen Bio to Present at the Jefferies Virtual Healthcare Conference

On May 26, 2020 Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, reported it will be featured as a presenting company at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 (Press release, Sesen Bio, MAY 26, 2020, View Source [SID1234558445]).

Event: Jefferies Virtual Healthcare Conference
Date: June 2, 2020
Time: 8:30 – 8:55 AM ET

A live webcast of the Company’s presentation will be accessible from the Investors & Media section of Sesen Bio’s website, www.sesenbio.com. An archived replay of the webcast will be available on the Company’s website for 90 days after the conference.